Printer Friendly

MERCK FILES NDA FOR SCHIZOPHRENIA MEDICATION

 BERWYN, Pa., Jan. 20 /PRNewswire/ -- Merck & Co., Inc. (NYSE: MRK) has filed a New Drug Application (NDA) with the Food and Drug Administration for Roxiam(R) (remoxipride), a medication for the treatment of acute and chronic schizophrenia.
 Merck acquired U.S. rights to Roxiam under an agreement with the Swedish pharmaceutical firm AB Astra.
 The 1982 agreement calls for the eventual formation of a separate U.S. joint venture company to be owned equally by Merck and Astra, after U.S. revenues from certain Astra products reach a specified level. Anticipating achievement of that goal, Merck created an internal management organization, the Astra/Merck Group, in 1992 to begin forming the future joint venture company.
 The Astra/Merck Group currently has a 500-person sales force in place marketing Prilosec(R) (omeprazole), to treat ulcers, and Plendil(R) (felodipine), to treat hypertension. Merck said it expects to launch Astra/Merck as an independent company in 1995.
 /delval/
 -0- 1/20/93
 /CONTACT: Roy Walker of Merck & Co., Inc., 215-652-6681/


CO: Merck & Co., Inc.; AB Astra; Astra/Merck Group ST: Pennsylvania IN: MTC SU: JVN

JS -- PH031 -- 7128 01/20/93 17:13 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1993
Words:192
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, WEDNESDAY, JAN. 20 /PRN/
Next Article:WASHINGTON STATE ENERGY OFFICE: TIPS TO STAY WARM DURING THE POWER OUTAGES
Topics:


Related Articles
MERCK FILES FOR FDA REVIEW OF THREE NEW PRODUCTS
ADVANCED POLYMER NDA FOR TRETINOIN ACNE TREATMENT ACCEPTED BY FDA FOR PREMARKET REVIEW
ASTRA MERCK STATEMENT ON AVAILABILITY OF LANSOPRAZOLE
CYTOGEN SUBMITS QUADRAMET(TM) NEW DRUG APPLICATION TO FDA
QUADRAMET(TM) NEW DRUG APPLICATION FILED BY FDA
DuPont Merck Submits New Drug Application For Investigational Anti-HIV Drug Sustiva(TM) (efavirenz)
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Submit New Drug Application for Aripiprazole.
Forest Laboratories Announces Acceptance of The NDA Filing for Acamprosate for the Treatment of Alcohol Dependence; Product Is Granted Expedited FDA...
Solvay Pharmaceuticals and Wyeth Announce Submission of New Drug Application for Bifeprunox to Treat Schizophrenia.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters